AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- Breaking Through Tumor Defenses With Next-Generation Cell Therapy
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- Active Versus Passive Shipping Solutions For Clinical Shipments
- January 2026 — CDMO Opportunities And Threats Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Evaluating The Expression Patterns Of Multiple Inhibitory Receptors
Discover how an innovative approach to interpreting T-cell exhaustion and inhibitory receptor expression is paving the way for innovative therapeutic approaches aimed at rejuvenating T-cell function.
-
The Advantages Of A Blended Learning Approach In Operator Training
Explore blended learning and its advantages over traditional operator training methods, which often reduce training to a repetitive but necessary checklist of reading and acknowledging procedures.
-
Producing MSC-Derived Cell Therapies From Isolation To Large-Scale Expansion
Explore the journey of producing MSC-derived cell therapies, from initial isolation and expansion to final product formulation and storage, and learn how to optimize each step.
-
Expansion Of Human Bone Marrow-Derived MSCs
Achieving over 870 million viable, quality mesenchymal stem/stromal cells is possible. This efficient cell culture method scales bone marrow-derived MSCs for clinical needs.
-
Select The Best Analyte: A Guide To Effective Mycoplasma Testing
As you build a Mycoplasma testing strategy to ensure drug safety, there are three analyte types to choose from: live Mycoplasma, RNA, and genomic DNA, each offering distinct advantages.
-
Proximal Tubule Kidney-Chip For Modeling Human Physiology
Discover how an Organ-Chip can be used to create a comprehensive recapitulation of the proximal tubule, addressing the need for more human-relevant preclinical models in the pharmaceutical industry.
-
Ensuring Product Safety And Purity With Mycoplasma And Sterility Testing
Discover how the Applied Biosystems™ MycoSEQ™ Plus system and Applied Biosystems™ SteriSEQ™ Rapid Sterility Testing System can help accelerate your cell therapy manufacturing process.
-
Injection Site Reaction Screening Methodology
Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.
-
Commercial Success Starts With A Fit-For-Purpose Flow Cytometer
Discover how standardizing reagents and automating flow cytometry workflows can improve reproducibility, reduce troubleshooting, and accelerate progress in cell-based therapies.
-
How To Unlock The Secret To Repeatable, Scalable Low Turnover
Here, we explore the evolution of a 10-year partnership and extrapolate the principles that create cohesive teams and minimize turnover.
NEWSLETTER ARCHIVE
- 03.03.26 -- STREAM Edition: Breakthrough In HER2 Immunotherapy For PMO With Paul Romness
- 03.03.26 -- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- 03.02.26 -- Navigating Conflicting Raw Material Preferences With Your CDMO
- 02.27.26 -- Optimize Your Cell And Gene Therapy Manufacturing Workflows
- 02.27.26 -- Active Versus Passive Shipping Solutions For Clinical Shipments
- Powering AI And Synthetic Biology In Therapy Design
- Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections